AVLN (Avalyn Pharma) OCF Margin %: 0.00% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

AVLN Avalyn Pharma Inc AVLN
11 GF Score
Price $28.50
View Full Analysis

What is Avalyn Pharma OCF Margin %?

Avalyn Pharma AVLN -1.01% 11 OCF Margin % is 0.00% as of Dec. 2025. GuruFocus rates AVLN with a GF Score™ of 11/100. Among 953 Biotechnology companies, Avalyn Pharma ranks worse than 104931.69% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Avalyn Pharma's Cash Flow from Operations for the six months ended in Dec. 2025 was $-81.48 Mil. Avalyn Pharma's Revenue for the six months ended in Dec. 2025 was $0.00 Mil. Therefore, Avalyn Pharma's OCF Margin % for the quarter that ended in Dec. 2025 was 0.00%.

As of today, Avalyn Pharma's current OCF Yield % is -6.45%.

The historical rank and industry rank for Avalyn Pharma's OCF Margin % or its related term are showing as below:


AVLN's OCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -64.23
* Ranked among companies with meaningful OCF Margin % only.

Avalyn Pharma OCF Margin % Related Terms

Avalyn Pharma OCF Margin % Historical Data

* Premium members only.

The historical data trend for Avalyn Pharma's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Avalyn Pharma OCF Margin % Chart

Avalyn Pharma Annual Data
Trend Dec24 Dec25
OCF Margin %
0.00 0.00

Avalyn Pharma Semi-Annual Data
Dec24 Dec25
OCF Margin % 0.00 0.00
AVLN
11GF Score
Avalyn Pharma Inc AVLN
OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Avalyn Pharma OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Avalyn Pharma's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-81.484/0
= %

Avalyn Pharma's OCF Margin for the quarter that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-81.484/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 0.00% mean?
Avalyn Pharma (AVLN) has a OCF Margin % of 0.00% as of Dec. 2025. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Avalyn Pharma and its competitors. According to the industry distribution chart, Avalyn Pharma ranks #999999 out of 953 companies in the Biotechnology industry.
Is Avalyn Pharma's OCF Margin % too high?
Avalyn Pharma's current OCF Margin % is 0.00%. Based on the distribution chart, Avalyn Pharma ranks #999999 out of 953 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Avalyn Pharma has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Avalyn Pharma's OCF Margin % compare to TRAX and IMTX?
According to the Biotechnology industry distribution chart, Avalyn Pharma ranks #999999 out of 953 companies for OCF Margin %. This places Avalyn Pharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Avalyn Pharma and its competitors. Avalyn Pharma's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avalyn Pharma stock overvalued right now?
Avalyn Pharma (AVLN) has a current OCF Margin % of 0.00%. The current OCF Margin % is 0.00%. Avalyn Pharma's overall GF Score™ is 11/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Avalyn Pharma (AVLN), the current OCF Margin % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Avalyn Pharma Business Description

Address 105 W First Street, Boston, MA, USA, 02127
Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.
11GF Score

Get the complete analysis for AVLN

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$28.50
Price